CTOs on the Move

DPT Laboratories

www.dptlabs.com

 
DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.dptlabs.com
  • 307 E Josephine St
    San Antonio, TX USA 78215
  • Phone: 210.476.8100

Executives

Name Title Contact Details

Similar Companies

Inkblot Therapy

Inkblottherapy.com offers affordable, secure video counselling any time, any place. We are on a mission to increase accessibility to high quality mental health counselling in Canada.

Ascend SpecialtyRx

Ascend SpecialtyRx is a Port Washington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

ExL Pharma

ExL Pharma is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.